Skip to Content

Vicente Valero, M.D., F.A.C.P.

Present Title & Affiliation

Primary Appointment

Deputy Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Valero has been with The University of Texas M. D. Anderson Cancer Center since June 1991, obtaining his M.D. from the Universidad Autonoma de Nuevo Leon, Facultad de Medicine, in 1980. Postgraduate training in Internal Medicine was completed at St. Elizabeth Hospital in Youngstown, Ohio, and Northeastern Ohio University College of Medicine in Rootstown, Ohio. Fellowships in Hematology-Medical Oncology were completed at the University of Cincinnati, Ohio, and at The University of Texas Medical Branch in Galveston, Texas. Board certifications include the American Board of Internal Medicine, the American Board of Medical Oncology, and the American Board of Hematology.

Publications include over 150 published articles in peer-reviewed journals, editorials and invited articles, 13 book chapters, and over 100 abstracts. He is an actively involved teacher in the Medical Oncology Continuing Clinic for Fellows and medical oncology and internal medicine residents at Lyndon B. Johnson General Hospital and The University of Texas M. D. Anderson Cancer Center, where he was honored as the Division of Medicine Teacher of the Year for the 1993-1994 and 1996-1997 academic years, and the Educator of the Month for December 2003. He is the primary investigator for several ongoing funded research protocols, and as an acknowledged leader in his fields of interest, he is a popular and much sought after speaker for local, national, and international presentations, and has given over 250 presentations, maintaining his belief that sharing all facets of the knowledge of breast cancer with other treating physicians and healthcare providers and educating the public about this disease may translate to improvement in its prevention, early detection, and treatment.

Research Interests

Dr. Valero utilizes a multidisciplinary approach to the treatment of breast cancer. His research interests include breast neoplasms, unusual histologies, new drug development, minority groups, and clinical trials with angiogenesis. More specifically, his primary focus is in the area of Her-2 neu amplified and ER+ HER-2 normal early, as well as metastatic breast cancer and novel biological agents, the management of patients with locally advanced breast cancer utilizing new biological agents and gene profiling, and clinical research targeting minority populations.

Education & Training

Degree-Granting Education

1980 Universidad Autonoma de Nuevo Leon, Facultad de Medicina, Monterrey, Nuevo Leon, Mexico, MD, Medicine

Postgraduate Training

7/1987-6/1988 Fellow, Hematology-Medical Oncology, Hematology-Medical Oncology, University of Texas Medical Branch, Department of Medicine, Galveston, TX, Frank H. Gardner MD
7/1985-6/1987 Fellow, Hematology-Medical Oncology, Hematology-Medical Oncology, University of Cincinnati Medical Center and Veterans Administration Hospital, Cincinnati, OH, Orlando Martelo MD
7/1982-6/1985 Internal Medicine: Resident, Internal Medicine, Saint Elizabeth Hospital Medical Center; Northeastern Ohio University College of Medicine, Youngstown; Rootstown, OH, Charles Wilkins MD
7/1982-6/1985 Internal Medicine: Resident, Internal Medicine, Northeastern Ohio University College of Medicine, Rootstown, OH, Charles Wilkins MD

Board Certifications

11/1988 American Board of Hematology
11/1987 American Board of Medical Oncology
9/1985 American Board of Internal Medicine


Academic Appointments

Associate Director, Nellie B. Connally Breast Center, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2014-present
Clinical Director, The Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2010-present

Honors and Awards

2010 The University Cancer Foundation Faculty Achievement Award in Patient Care, UT Faculty Senate
2008-present America's Top Oncologists, Consumers' Research Council of America
2007 Gerald P. Bodey Award for Excellence in Education, UT MDACC - Div of Cancer Medicine
2006-present America's Top Doctors for Cancer, Castle Connolly Medical Ltd.
2006-present Best Doctors in America,
2006-present Houston's Top Doctors, H TEXAS magazine
2005-present Texas Super Doctors, Texas Monthly, December issues
2003 Educator of the Month, The University of Texas M. D. Anderson Cancer Center
2002 Who's Who in Medicine and Healthcare, 4th Ed, Marquis Who's Who, New Providence, NJ
2002 Who's Who in Science and Engineering, 7th Ed, Marquis Who's Who, New Providence, NJ
2001-present America's Top Doctors, 1st-7th editions, JJ Connolly (Ed.), Castle Connolly Medical Ltd., New York, NY
2001 Fellow, American College of Physicians
2001 Top Breast Cancer Doctors in America, Redbook 197(4):30-42, October 2001
1993 Teacher of the Year Award, 1993 and 1996, The University of Texas M. D. Anderson Cancer Center
1979 Medical School, Senior Year, Universidad Autonoma de Nuevo Leon, Facultad de Medicina

Selected Publications

Peer-Reviewed Original Research Articles

1. Bishop AJ, Ensor J, Moulder SL, Shaitelman SF, Edson MA, Whitman GJ, Bishnoi S, Hoffman KE, Stauder MC, Valero V, Buchholz TA, Ueno NT, Babiera G, Woodward WA. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer 121(24):4324-32, 12/15/2015. e-Pub 9/8/2015. PMID: 26348887.
2. Shaitelman SF, Tereffe W, Dogan BE, Hess KR, Caudle AS, Valero V, Stauder MC, Krishnamurthy S, Candelaria RP, Strom EA, Woodward WA, Hunt KK, Buchholz TA, Whitman GJ. Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. Int J Radiat Oncol Biol Phys 93(1):102-10, 9/1/2015. e-Pub 5/16/2015. PMID: 26279028.
3. Chaudry M, Lei X, Gonzalez-Angulo AM, Mittendorf EA, Valero V, Tripathy D, Hortobagyi GN, Chavez-MacGregor M. Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 153(2):417-23, 9/2015. e-Pub 8/14/2015. PMID: 26272743.
4. Subbiah IM, Lei X, Weinberg JS, Sulman EP, Chavez-MacGregor M, Tripathy D, Gupta R, Varma A, Chouhan J, Guevarra RP, Valero V, Gilbert MR, Gonzalez-Angulo AM. Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. J Clin Oncol 33(20):2239-45, 7/10/2015. e-Pub 5/18/2015. PMID: 25987700.
5. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Erratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat 152(2):417, 7/2015. PMID: 26092296.
6. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat 152(2):407-16, 7/2015. e-Pub 5/29/2015. PMCID: PMC4492876.
7. Anderson KO, Palos GR, Mendoza TR, Cleeland CS, Liao KP, Fisch MJ, Garcia-Gonzalez A, Rieber AG, Nazario LA, Valero V, Hahn KM, Person CL, Payne R. Automated pain intervention for underserved minority women with breast cancer. Cancer 121(11):1882-90, 6/1/2015. e-Pub 2/24/2015. PMCID: PMC4527331.
8. Tsai CJ, Li J, Gonzalez-Angulo AM, Allen PK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Yang W, Cristofanilli M, Valero V, Buchholz TA. Outcomes after Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-Directed Therapy. Am J Clin Oncol 38(3):242-7, 6/2015. e-Pub 5/2/2013. PMCID: PMC3880388.
9. Bayraktar S, Jackson M, Gutierrez-Barrera AM, Liu D, Meric-Bernstam F, Brandt A, Woodson A, Litton J, Lu KH, Valero V, Arun BK. Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers. Breast J 21(3):260-7, May-Jun, 5/2015. e-Pub 3/19/2015. PMID: 25789811.
10. Parinyanitikul N, Lei X, Chavez-MacGregor M, Liu S, Mittendorf EA, Litton JK, Woodward W, Zhang AH, Hortobagyi GN, Valero V, Meric-Bernstam F, Gonzalez-Angulo AM. Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. Clin Breast Cancer 15(2):153-60, 4/2015. e-Pub 10/2/2014. PMID: 25454687.
11. Mego M, Zuo Z, Gao H, Cohen EN, Giordano A, Tin S, Anfossi S, Jackson S, Woodward W, Ueno NT, Valero V, Alvarez RH, Hortobagyi GN, Khoury JD, Cristofanilli M, Reuben JM. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. Thromb Haemost 113(3):593-8, 3/2015. e-Pub 11/6/2014. PMID: 25373787.
12. Kai M, Kogawa T, Liu DD, Fouad TM, Kai K, Niikura N, Hsu L, Willey JS, Theriault RL, Valero V, Ueno NT. Clinical Characteristics and Outcome of Bone-Only Metastasis in Inflammatory and Noninflammatory Breast Cancers. Clin Breast Cancer 15(1):37-42, 2/2015. e-Pub 8/15/2014. PMID: 25258308.
13. Malouf GG, Zhang J, Yuan Y, Compérat E, Rouprêt M, Cussenot O, Chen Y, Thompson EJ, Tannir NM, Weinstein JN, Valero V, Khayat D, Spano JP, Su X. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. Mol Oncol 9(1):32-43, 1/2015. e-Pub 7/25/2014. PMCID: PMC4516270.
14. Kogawa T, Fouad TM, Wei C, Masuda H, Kai K, Fujii T, El-Zein R, Chavez-MacGregor M, Litton JK, Brewster A, Alvarez RH, Hortobagyi GN, Valero V, Theriault R, Ueno NT. Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. J Cancer 6(4):310-8, 2015. e-Pub 1/22/2015. PMCID: PMC4349870.
15. Mego M, Giordano A, De Giorgi U, Masuda H, Hsu L, Giuliano M, Fouad TM, Dawood S, Ueno NT, Valero V, Andreopoulou E, Alvarez RH, Woodward WA, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res 17:2, 2015. e-Pub 1/9/2015. PMCID: PMC4318180.
16. Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Triple Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents. Mol Cancer Ther 13(12):3175-84, 12/2014. e-Pub 9/24/2014. PMCID: PMC4258414.
17. Johnston FM, Tergas AI, Bennett JL, Valero V, Morrissey CK, Fader AN, Hobson DB, Weaver SJ, Rosen MA, Wick EC. Measuring Briefing and Checklist Compliance in Surgery: A Tool for Quality Improvement. Am J Med Qual 29(6):491-8, 11/2014. e-Pub 11/22/2013. PMID: 24270170.
18. Su X, Malouf GG, Chen Y, Zhang J, Yao H, Valero V, Weinstein JN, Spano JP, Meric-Bernstam F, Khayat D, Esteva FJ. Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. Oncotarget 5(20):9864-76, 10/30/2014. e-Pub 9/8/2014. PMCID: PMC4259443.
19. Pusztai L, Moulder S, Altan M, Kwiatkowski D, Valero V, Ueno NT, Esteva FJ, Avritscher R, Qi Y, Strauss L, Hortobagyi GN, Hatzis C, Symmans WF. Gene Signature-Guided Dasatinib Therapy in Metastatic Breast Cancer. Clin Cancer Res 20(20):5265-71, 10/15/2014. e-Pub 8/29/2014. PMID: 25172932.
20. Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, Alvarez RH, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res 16(5). e-Pub 9/16/2014. PMID: 25223629.
21. Abouharb S, Ensor J, Loghin ME, Katz R, Moulder SL, Esteva FJ, Smith B, Valero V, Hortobagyi GN, Melhem-Bertrandt A. Leptomeningeal disease and breast cancer: the importance of tumor subtype. Breast Cancer Res Treat 146(3):477-86, 8/2014. e-Pub 7/20/2014. PMID: 25038877.
22. Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer 120(13):1932-8, 7/1/2014. e-Pub 3/26/2014. PMID: 24677057.
23. Debeb BG, Gong Y, Atkinson RL, Sneige N, Huo L, Gonzalez-Angulo A, Hung MC, Valero V, Ueno NT, Woodward WA. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. J Exp Clin Cancer Res 33(1). e-Pub 7/23/2014. PMID: 25051981.
24. Campos-Gomez S, Valero V, Flores-Arredondo JH, Isassi-Chapa A, Rangel-Rodríguez I, Hortobagyi GN, Gonzalez-Angulo AM. Breast Cancer Subtype and Baseline Characteristics from Diabetic Breast Cancer Patients are Not Different from Nondiabetics. Breast J 20(4):434-6, Jul-Aug, 7/2014. e-Pub 5/26/2014. PMID: 24862358.
25. Valero V. Carboplatin for early triple-negative breast cancer? Lancet Oncol 15(7):676-8, 6/2014. PMID: 24872096.
26. McBride A, Allen P, Woodward W, Kim M, Kuerer HM, Drinka EK, Sahin A, Strom EA, Buzdar A, Valero V, Hortobagyi GN, Hunt KK, Buchholz TA. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys 89(2):392-8, 6/2014. e-Pub 4/2014. PMID: 24721590.
27. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC vs. the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Ann Oncol 25(6):1122-7, 6/2014. e-Pub 3/2014. PMCID: PMC4037860.
28. Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, Zinner R, Subbiah V, Fu S, Schwab R, Moulder S, Valero V, Schwaederle M, Yelensky R, Miller VA, Stephens MP, Meric-Bernstam F, Kurzrock R. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget 5(9):2349-54, 5/15/2014. e-Pub 5/2014. PMCID: PMC4058010.
29. Ratcliff CG, Lam CY, Arun B, Valero V, Cohen L. Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer. Psychooncology. e-Pub 4/2014. PMID: 24706506.
30. Eckmann K, Michaud LB, Rivera E, Madden TL, Esparza-Guerra L, Kawedia J, Booser DJ, Green MC, Hortobagyi GN, Valero V. Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases. J Oncol Pharm Pract 20(2):120-9, 4/2014. e-Pub 5/14/2013. PMID: 23676510.
31. Gagliato Dde M, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, Hortobagyi GN, Chavez-Macgregor M. Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer. J Clin Oncol 32(8):735-44, 3/10/2014. e-Pub 1/27/2014. PMCID: PMC3940536.
32. Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-Macgregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol 25(2):384-91, 2/2014. e-Pub 12/2013. PMCID: PMC3905780.
33. Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, Garza RJ, Debeb BG, Alvarez RH, Valero V, Hortobagyi GN, Calin GA, Ueno NT, Woodward WA, Reuben JM. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One 9(1):e83113, 2014. e-Pub 1/8/2014. PMCID: PMC3885405.
34. Abdayem P, Ghosn M, Valero V, Walters R, Arun B, Murray JL, Theriault R, Frye D, Ibrahim NK. Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature. J Cancer 5(5):351-9, 2014. e-Pub 3/29/2014. PMCID: PMC3982182.
35. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential response to neoadjuvant chemotherapy among triple-negataive breast cancer molecular 7-subtypes. Clin Cancer Res 19(19):5533-5540, 10/1/2013. e-Pub 8/15/2013. PMCID: PMC3813597.
36. Vahdat LT, Vrdoljak E, Gómez H, Li RK, Bosserman L, Sparano JA, Baselga J, Mukhopadhyay P, Valero V. Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. J Geriatr Oncol 4(4):346-52, 10/2013. e-Pub 8/23/2013. PMID: 24472478.
37. Andreopoulou E, Vigoda IS, Valero V, Hershman DL, Raptis G, Vahdat LT, Han HS, Wright JJ, Pellegrino CM, Cristofanilli M, Alvarez RH, Fehn K, Fineberg S, Sparano JA. Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma. Breast Cancer Res Treat 141(3):429-35, 10/2013. e-Pub 9/26/2013. PMCID: PMC3999640.
38. Esmaeli B, Valero V. Epiphora and Canalicular Stenosis Associated With Adjuvant Docetaxel in Early Breast Cancer: Is Excessive Tearing Clinically Important? J Clin Oncol 31(17):2076-2077, 6/10/2013. e-Pub 5/6/2013. PMID: 23650413.
39. Bayraktar S, Gutierrez-Barrera AM, Lin H, Elsayegh N, Tasbas T, Litton JK, Ibrahim NK, Morrow PK, Green M, Valero V, Booser DJ, Hortobagyi GN, Arun BK. Outcome of Metastatic Breast Cancer in Selected Women with or without Deleterious BRCA Mutations. Clin Exp Metastasis 30(5):631-42, 6/2013. e-Pub 2/1/2013. PMID: 23370825.
40. Valero V. Managing Ixabepilone Adverse Events With Dose Reduction. Clin Breast Cancer 13(1):1-6, pii: S1526-8209(12)00182-6. doi: 10.1016/j.clbc.2012.09.003, 2/2013. e-Pub 10/24/2012. PMID: 23098573.
41. Liu NW, Sanford T, Srinivasan R, Liu JL, Khurana K, Aprelikova O, Valero V, Bechert C, Worrell R, Pinto PA, Yang Y, Merino M, Linehan WM, Bratslavsky G. Impact of ischemia and procurement conditions on gene expression in renal cell carcinoma. Clin Cancer Res 19(1):42-9, 1/1/2013. e-Pub 11/7/2012. PMCID: PMC3658320.
42. Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Res Treat 137(2):631-6, 1/2013. e-Pub 12/15/2012. PMCID: PMC3867793.
43. Bayraktar S, Gutierrez Barrera AM, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y, Symmans F, Arun B. USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women with Breast Cancer. Cancer J 19(1):10-17, Jan-Feb, 1/2013. PMCID: PMC3568679.
44. Lynch SP, Lei X, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang H, Hortobágyi GN, Gonzalez-Angulo AM, Valero V. Breast Cancer Multifocality and Multicentricity and Locoregional Recurrence. Oncologist 18(11):1167-73, 2013. e-Pub 10/17/2013. PMCID: PMC3825299.
45. Krishnamurthy S, Woodward W, Yang W, Reuben JM, Tepperberg J, Ogura D, Niwa S, Huo L, Gong Y, El-Zein R, Gonzalez-Angulo AM, Chavez-Macgregor M, Alvarez R, Lucci A, Valero V, Ueno NT. Status of the Anaplastic Lymphoma Kinase (ALK) gene in inflammatory breast carcinoma. Springerplus 28(2):409, 2013. e-Pub 8/28/2013. PMCID: PMC3797914.
46. Lynch SP, Lei X, Chavez-MacGregor M, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang A, Hortobagyi GN, Valero V, Gonzalez-Angulo AM. Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol 23(12):3063-9, 12/2012. e-Pub 7/9/2012. PMCID: PMC3501230.
47. Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM. Epithelial-Mesenchyman Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. Mol Cancer Ther 11(11). e-Pub 9/2012. PMID: 22973057.
48. Walker GV, Niikura N, Yang W, Rohren E, Valero V, Woodward WA, Alvarez RH, Lucci A, Ueno NT, Buchholz TA. Pretreatment Staging Positron Emission Tomography/Computed Tomography in Patients With Inflammatory Breast Cancer Influences Radiation Treatment Field Designs. Int J Radiat Oncol Biol Phys 83(5):1381-6, 8/1/2012. e-Pub 1/26/2012. PMID: 22284689.
49. Valero V, Vrdoljak E, Xu B, Thomas E, Gómez H, Manikhas A, Medina C, Li RK, Ro J, Bosserman L, Vahdat L, Mukhopadhyay P, Opatt D, Sparano JA. Maintenance of Clinical Efficacy After Dose Reduction of Ixabepilone Plus Capecitabine in Patients With Anthracycline- and Taxane-Resistant Metastatic Breast Cancer: A Retrospective Analysis of Pooled Data from 2 Phase III Randomized Clinical Trials. Clin Breast Cancer 12(4):240-6, 8/2012. e-Pub 6/2012. PMID: 22658378.
50. Alvarez RH, Gong Y, Ueno NT, Alizadeh PA, Hortobagyi GN, Valero V. Metastasis in the Breast Mimicking Inflammatory Breast Cancer. J Clin Oncol 30(22):e202-6, 8/2012. e-Pub 6/2012. PMID: 22734030.
51. De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M. Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer. Clin Breast Cancer 12(4):26-9, 8/2012. e-Pub 5/15/2012. PMID: 22591634.
52. Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Vidaurre T, Gomez H, Valero V, Hortobagyi GN, Symmans WF, Bottai G, Di Leo A, Gonzalez-Angulo AM, Pusztai L. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat 134(1):333-43, 7/2012. e-Pub 4/27/2012. PMID: 22538770.
53. Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Driga A, Damaraju S, Sliwkowski MX, Robert NJ, Valero V, Crown J, Falkson C, Brufsky A, Pienkowski T, Eiermann W, Martin M, Bee V, Marathe O, Slamon DJ, Timmerman JM. Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients. Clin Cancer Res 18(12):3478-3486, 6/15/2012. e-Pub 4/13/2012. PMID: 22504044.
54. Brufsky A, Valero V, Tiangco B, Dakhil S, Brize A, Rugo HS, Rivera R, Duenne A, Bousfoul N, Yardley DA. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 133(3):1067-75, 6/2012. e-Pub 3/14/2012. PMID: 22415477.
55. Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of Neoadjuvant Therapy with Trastuzumab Concurrent with Anthracycline- and Non-anthracycline-based Regimens for HER2-Positive Breast Cancer. Cancer 118(9):2385-93, 5/1/2012. e-Pub 9/27/2011. PMCID: PMC3274632.
56. Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 23(5):1144-50, 5/2012. e-Pub 9/2011. PMID: 21965473.
57. Abbott DE, Brouquet A, Mittendorf EA, Andreou A, Meric-Bernstam F, Valero V, Green MC, Kuerer HM, Curley SA, Abdalla EK, Hunt KK, Vauthey JN. Resection of liver metastases from breast cancer: Estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery 151(5):710-6, 5/2012. e-Pub 1/29/2012. PMID: 22285778.
58. Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, Valero V, Fritsche HA, Cristofanilli M. Comparison of assay methods fro detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest Breast Cancer Select/Detect versus Veridex CellSearch System. Int J Cancer 130(7):1590-7, 4/1/2012. e-Pub 11/30/2011. PMID: 21469140.
59. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Identifying factors that impact survival among women with inflammatory breast cancer. Ann Oncol 23(4):870-5, 4/2012. e-Pub 7/15/2011. PMID: 21765048.
60. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry. J Clin Oncol 30(7):729-34, 3/1/2012. e-Pub 1/30/2012. PMID: 22291085.
61. Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III Trial Evaluating Weekly Paclitaxel Versus Docetaxel in Combination With Capecitabine in Operable Breast Cancer. J Clin Oncol 30(9):930-5, 3/20/2012. e-Pub 2/13/2012. PMID: 22331946.
62. Arun B, Valero V, Liu D, Brewster A, Green M, Gutierrez-Barrera A, Akar U, Rivera E, Esteva FJ, Buzdar AU, Hortobagyi GN, Sneige N. Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. Cancer Prev Res (Phila) 5(2):276-82, 2/2012. e-Pub 11/18/2011. PMID: 22102688.
63. Kelley BP, Valero V, Yi M, Kronowitz SJ. Tamoxifen Increases the Risk of Microvascular Flap Complications in Patients Undergoing Microvascular Breast Reconstruction. Plast Reconstr Surg 129(2):305-14, 2/2012. e-Pub 10/7/2011. PMID: 21987043.
64. Chavez-Macgregor M, Brown E, Lei X, Litton J, Meric-Bernstram F, Mettendorf E, Hernandez L, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer 118(2):326-32, 1/2012. e-Pub 5/2011. PMCID: PMC3158806.
65. Lester TR, Hunt KK, Nayeemuddin KM, Bassett RL, Gonzalez-Angulo AM, Feig BW, Huo L, Rourke LL, Davis WG, Valero V, Gilcrease MZ. Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat 131(1):41-8, 1/2012. e-Pub 2/18/2011. PMID: 21331622.
66. Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, Iwamoto T, Krishnamurthy S, Yang W, Reuben JM, Hortobágyi GN, Ueno NT. Inflammatory Breast Cancer: What We Know and What We Need to Learn. Oncologist 17(7):891-9, 2012. e-Pub 5/14/2012. PMID: 22584436.
67. Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V, Cristofanilli M. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer 117(24):5476-84, 12/2011. e-Pub 6/2011. PMID: 21713757.
68. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA. Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer. The Oncologist 16(12), Dec 6. e-Pub 12/2011. PMCID: PMCPMC3248766.
69. Slamon D, Eierman W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane T, Tabah-Fisch T, Lindsay MA, Riva A, Crown J. Adjuvant Trastuzumab in HER-2 Positive Breast Cancer. NEJM 365(14):1273-83, 10/2011.
70. Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III Randomized Trial Of Dose Intensive Neoadjuvant Chemotherapy With Or Without G-CSF In Locally Advanced Breast Cancer: Long-Term Results. The Oncologist 16(11):1527-34, 2011, 10/2011. PMCID: PMC3233286.
71. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol 29(32), 2011 Nov 10. e-Pub 10/2011. PMID: 21990397.
72. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience. J Clin Oncol 29(28), 2011 Oct 1. e-Pub 9/2011. PMID: 21900106.
73. Durak MG, Gonzalez-Angulo AM, Hanrahan EO, Broglio KR, Valero V, Hortobagyi GN, Hunt KK, Sahin AA. Age and Associated Fibrocystic Changes are Prognostically Significant in Patients with Small Node-Negative (T1a,bN0) Invasive Breast Cancer. Breast J. e-Pub 7/5/2011. PMID: 21726347.
74. Mego M, De Giorgi U, Dawood S, Wang X, Valero V, Andreopoulou E, Handy B, Ueno NT, Reuben JM, Cristofanilli M. Characterization of metastatic breast cancer patients with non-detectable circulating tumor cells. Int J Cancer 129(2):417-23, 7/15/2011. e-Pub 11/28/2010. PMID: 20857493.
75. Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29(19):2628-34, 7/1/2011. e-Pub 5/23/2011. PMID: 21606433.
76. Valero V, Wingate H, Chada S, Liu Y, Palalon F, Mills G, Keyomarsi K, Hunt KK. MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells. Cancer Gene Ther 18(7):510-9, 7/2011. e-Pub 5/6/2011. PMID: 21546925.
77. Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 13(3). e-Pub 6/15/2011. PMID: 21699723.
78. Kronowitz SJ, Lam C, Terefe W, Hunt KK, Kuerer HM, Valero V, Lance S, Robb GL, Feng L, Buchholz TA. A multidisciplinary protocol for planned skin-preserving delayed breast reconstruction for patients with locally advanced breast cancer requiring postmastectomy radiation therapy: 3-year follow-up. Plast Reconstr Surg 127(6):2154-66, 6/2011. e-Pub 2/2011. PMID: 21311392.
79. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305(18):1873-81, 5/11/2011. PMID: 21558518.
80. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: A large population-based study. Cancer 117(9):1819-26, 5/1/2011. e-Pub 11/29/2010. PMID: 21509759.
81. Palos GR, Mendoza TR, Liao KP, Anderson KO, Garcia-Gonzalez A, Hahn K, Nazario A, Ramondetta LM, Valero V, Lynch GR, Jibaja-Weiss ML, Cleeland CS. Caregiver symptom burden: The risk of caring for an underserved patient with advanced cancer. Cancer 117(5):1070-79, 3/1/2011. e-Pub 10/19/2010. PMCID: PMC3065823.
82. Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM, Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson F, Symmans WF, Pusztai L, Ueno NT. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat 125(3):785-95, 2/2011. e-Pub 12/9/2010. PMID: 21153052.
83. Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey JR, Fumoleau P, Rolski J, Mrsic-Krmpotic Z, Jagiello-Gruszfeld A, Riva A, Buyse M, Taupin H, Sauter G, Press MF, Slamon DJ. Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens. J Clin Oncol 29(2):149-156, 1/2011. e-Pub 11/2010. PMID: 21115860.
84. Alvarez RH, Valero V, Hortobagyi GN. Ixabepilone for the treatment of breast cancer. Ann Med 43(6):477-86, 2011. e-Pub 5/2011. PMID: 21585248.
85. Dawood S, Ueno NT, Valero V, Andreopoulou E, Hsu L, Lara J, Woodward W, Buchholz TA, Hortobagyi GN, Cristofanilli M. Incidence of and survival following brain metastases among women with inflammatory breast cancer. Ann Oncol 21(12):2348-55, 12/2010. e-Pub 5/3/2010. PMID: 20439340.
86. Valero V, Kong AL, Hunt KK, Yi M, Hwang RF, Meric-Bernstam F, Bedrosian I, Ross MI, Babiera GV, Litton JK, Mittendorf EA. Sentinel lymph node dissection is technically feasible in older breast cancer patients. Clin Breast Cancer 10(6):477-82, Dec 2010, 12/2010. PMID: 21147692.
87. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer. e-Pub 11/29/2010. PMID: 21117228.
88. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez HL, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon EA, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans F, Pusztai L. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 16(21):5351-61, November 2010, 11/2010. PMID: 20829329.
89. Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WF, Gianni L, Pusztai L. Prognostic and Therapeutic Implications of Distinct Kinase Expression Patterns in Different Subtypes of Breast Cancer. Cancer Res 70(21):8852-62, November 1, 2010, 11/2010. e-Pub 10/2010. PMID: 20959472.
90. Cheng YC, Valero V, Davis ML, Green MC, Gonzalez-Angulo AM, Theriault RL, Murray JL, Hortobagyi GN, Ueno NT. Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients. Br J Cancer 103(9):1331-4, 10/26/2010. e-Pub 9/28/2010. PMCID: PMC2990606.
91. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ, Hortobagyi GN, Pusztai L. Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer. J Clin Oncol 28(27):4111-19, Sep 20, 2010, 9/2010. e-Pub 8/2010. PMID: 20697068.
92. Carlson RW, Theriault R, Schurman CM, Rivera E, Chung CT, Phan SC, Arun B, Dice K, Chiv VY, Green M, Valero V. Phase II Trial of Anastrozole Plus Goserelin in the Treatment of Hormone Receptor-Positive, Metastatic Carcinoma of the Breast in Premenopausal Women. J Clin Oncol 28(25):3917-21, Sep 1, 2010, 9/2010. e-Pub 8/2010. PMID: 20679610.
93. De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT. F-18-FDG PET/CT Findings and Circulating Tumor Cell Counts in the Monitoring of Systemic Therapies for Bone Metastases from Breast Cancer. J Nucl Med 51(8):1213-1218, Aug 1 2010, 8/2010.
94. Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L. Molecular anatomy of breast cancer stroma and its prognostic value in ER-positive and -negative cancers. J Clin Oncol 28(28), 10/01/2010. e-Pub 8/2010. PMID: 20805453.
95. Alvarez RH, Valero V, Hortobagyi GN. Emerging Targeted Therapies for Breast Cancer. J Clin Oncol 28(20):3366-79, July 7 2010, 7/2010. e-Pub 6/2010. PMID: 20530283.
96. Dawood S, Gong Y, Broglio K, Buchholz TA, Woodward W, Lucci A, Valero V, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M. Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome. Breast J 16(5):529-532, 7/2010. e-Pub 7/2010. PMID: 20626396.
97. Reuben JM, Lee BN, Li C, Gao H, Broglio KR, Valero V, Jackson SA, Ueno NT, Krishnamurthy S, Hortobagyi GN, Cristofanilli M. Circulating Tumor Cells and Biomarkers: Implications for Personalized Targeted Treatments for Metastatic Breast Cancer. Breast J 16(3):327-30, May-Jun, 5/2010. e-Pub 4/12/2010. PMID: 20408820.
98. Chavez-Macgregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM. Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer 116(17), Sep 1, 2010. e-Pub 5/2010. PMID: 20564153.
99. Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans WF, Desmedt C, Haibe-Kains B, Sotiriou C, Pusztai L, Swanton C. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 11(4):358-65,, 4/2010. e-Pub 2/26/2010. PMID: 20189874.
100. Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 16(6):1904-14, 3/15/2010. e-Pub 3/9/2010. PMID: 20215537.
101. Alvarez RH, Booser DJ, Cristofanilli M, Sahin AA, Strom EA, Guerra L, Kau SW, Gonzalez-Angulo AM, Hortobagyi GN, Valero V. Phase II trial of primary systemic therapy with doxorubicin and docetaxel, followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer: Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099. Cancer 116(5):1210-1217, 3/1/2010. PMID: 20082452.
102. Moulder SL, Holmes FA, Tolcher AW, Thall P, Broglio K, Valero V, Buzdar AU, Arbuck SG, Seidman A, Hortobagyi GN. A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer 116(4):814-21, 2/15/2010. PMID: 20052721.
103. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28(3):453-9, 1/20/2010. e-Pub 12/14/2009. PMCID: PMC2815707.
104. De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol 21(1):33-9, 1/2010. e-Pub 7/14/2009. PMID: 19602564.
105. Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, Nikolsky Y, Tsyganova M, Ishkin A, Nikolskaya T, Hess KR, Valero V, Booser D, Delorenzi M, Hortobagyi GN, Shi L, Symmans WF, Pusztai L. Effect of training sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 12(1):R5, 2010. e-Pub 1/11/2010. PMCID: PMC2880423.

Grant & Contract Support

Title: A randomized, phase II, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of MetMab in combination with paclitaxel and bevacizumab in patients with metastatic, triple-negative breast cancer
Funding Source: Genentech Inc
Role: Principal Investigator
Duration: 7/1/2011 - 2/28/2015
Title: A Phase II randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel and Neratinib or Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2 Positive Breast Cancer NSABPFB-7
Funding Source: NSABP
Role: Principal Investigator
Duration: 4/26/2011 - 4/30/2013
Title: A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive
Funding Source: NSABP
Role: Principal Investigator
Duration: 10/26/2010 - 10/31/2012
Title: A clinical trial to determine the efficacy of five years of letrozole compared to placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor positive breast cancer
Funding Source: NSABP
Role: Principal Investigator
Duration: 10/1/2008 - 1/31/2013
Title: Human Breast Cancer Stem Cell Surrogates
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/25/2008 - 7/31/2013
Title: A phase II trial of arimidex plus zoladex in the treatment of hormone receptor positive carcionoma of the breast in premenopausal women
Funding Source: AstraZeneca
Role: Principal Investigator
Duration: 8/22/2002 - 8/19/2012

Last updated: 12/30/2015